Skip to content

BCBS Alabama

Does BCBS Alabama cover Zepbound?

Yes. BCBS Alabama covers Zepbound for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 30 kg/m2 (or ≥ 23 kg/m2 for South Asian, Southeast Asian, East Asian adults)

Adult overweight with comorbidity

All of:

  • Age ≥ 18 years
  • BMI ≥ 27 kg/m2 (or ≥ 23 kg/m2 for South Asian, Southeast Asian, East Asian adults)

Plus any one of:

  • Hypertension
  • Type 2 diabetes
  • Dyslipidemia
  • OSA
  • CVD
  • MASH
  • other weight-related comorbidity

Documentation to bring

  • Baseline BMI documentation meeting threshold (≥ 30 kg/m2, or ≥ 27 kg/m2 with comorbidity, or ≥ 23 kg/m2 for qualifying Asian ethnicities)
  • Documentation of qualifying weight-related comorbidity if BMI 27–29.9 kg/m2
  • Documentation of reduced-calorie diet and increased physical activity as adjunct

Approval and renewal

  • Renewal: At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation per guideline-based efficacy assessment standard cited in document.
  • Renewal: At least 12 weeks on therapy before the first renewal.

Not covered when

  • Coadministration with other tirzepatide-containing products not recommended
  • Coadministration with any GLP-1 receptor agonist not recommended
  • Pregnancy

Policy note: Covers both Zepbound subcutaneous injection solution vial and Zepbound KwikPen formulations. Adult-only FDA indication for weight loss (no pediatric indication for tirzepatide at time of policy). The 5% weight loss threshold at 12 weeks is cited from guidelines as the efficacy assessment standard applicable to all weight management agents.

Policy effective April 20, 2026 · verified June 2, 2026 · source: Albp Weight Management Paql Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Moderate-to-severe OSA in adults with obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 30 kg/m2 (obesity)
  • Diagnosis of moderate-to-severe OSA confirmed by PSG or HSAT (AHI/REI ≥ 15 events/hour for moderate; ≥ 30 for severe)

Plus any one of:

  • Not currently receiving PAP therapy (can receive Zepbound with or without PAP per SURMOUNT-OSA trials)
  • Currently receiving PAP therapy (SURMOUNT-OSA Trial 2 included PAP users)

Documentation to bring

  • Diagnosis of moderate-to-severe OSA confirmed by polysomnography (PSG) or home sleep apnea test (HSAT) with AHI or REI ≥ 15 events/hour
  • Baseline BMI documentation ≥ 30 kg/m2
  • Sleep study results (PSG or HSAT report) documenting AHI/REI severity
  • Documentation of reduced-calorie diet and increased physical activity as adjunct

Not covered when

  • Craniofacial abnormalities affecting respiration (per SURMOUNT-OSA exclusion criteria cited in document)
  • Predominantly central or mixed sleep apnea (≥ 50% central or mixed apneas/hypopneas)
  • Cheyne-Stokes respiration
  • Obesity hypoventilation syndrome
  • Daytime hypercapnia
  • Coadministration with other tirzepatide-containing products not recommended
  • Coadministration with any GLP-1 receptor agonist not recommended
  • Pregnancy

Policy note: OSA indication requires obesity (BMI ≥ 30) per FDA label. Moderate-to-severe OSA defined as AHI ≥ 15 events/hour (moderate 15-29, severe ≥ 30). The SURMOUNT-OSA program enrolled both PAP-naive (Trial 1) and PAP-using (Trial 2) patients; PAP trial is NOT required as a prerequisite. AHI from PSG is the preferred diagnostic index; REI from HSAT is acceptable but may underestimate severity. RDI may identify arousal-based disease not fully captured by AHI/REI. Document extensively discusses OSA diagnostic methodology (PSG vs HSAT, AHI vs REI vs RDI, hypopnea scoring rules) as clinical rationale. The OSA ahi min of 15 is inferred from 'moderate-to-severe' OSA definition per AASM standard referenced in the document; the document does not explicitly state a specific AHI threshold as a PA requirement but references moderate-to-severe as the qualifying severity. PAP therapy use is not required prior to Zepbound; patients on PAP or not on PAP may qualify.

Policy effective April 20, 2026 · verified June 2, 2026 · source: Albp Weight Management Paql Prog Sum · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Alabama cover Zepbound?
Yes. BCBS Alabama covers Zepbound for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
What does BCBS Alabama require to renew Zepbound?
Weight Loss — Applies to Employer and ACA Marketplace plans. At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation per guideline-based efficacy assessment standard cited in document. At least 12 weeks on therapy before the first renewal.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Alabama: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Alabama Medicaid, BCBS Arizona, BCBS Arkansas, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska, BCBS North Carolina

All insurance plans · All medications

Summary of BCBS Alabama's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.